-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Liraglutide is an alamide-based GLP-1 perturbation agent developed by Noor and Nord, first listed in the European Union in July 2009 and entered the Chinese market in 2011.
blood sugar dependence promotes insulin secretion, simulates the body's own endocrine, protects islet β cells, and delays stomach emptying to reduce appetite.
2017 Lilaglutide injections are included in the National Health Insurance Directory.
At present, only the original Yanno and Nord's Lilaglutide injections were approved for sale, with different classifications and different processes to express the system of declaration of enterprises approved clinical has Tonghua Dongbao, Shenzhen Hanyu, Chengdu Sanno, Zhuhai Federal Pharmaceuticals and other eight.
our company developed a unique Lilaglutide process, to achieve better consistency with the original research quality standards and processes.
.